The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.



Latest Headlines

Latest Headlines

Novartis team tracks remissions of 4-plus years in a pioneering CAR-T study

Five years after the University of Pennsylvania began recruiting a small group of 14 patients with hard-to-treat chronic lymphocytic leukemia, researchers are still tracking three of them who are still alive with no signs of their cancer returning after being treated with a first-generation CAR-T therapy.

European pharma lobby says 'non' to French funding for off-label Avastin

The French government recently said "oui" to Roche's ($RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related macular degeneration (AMD), prompting a resounding "non" from the pharma industry, which is none-too-pleased with the country's latest move.

In neuroscience swap, Amgen buys into Novartis' BACE drug program for Alzheimer's

Amgen is buying into Novartis' early-stage BACE program for Alzheimer's, paying an unspecified upfront and milestones in exchange for a cut of the program, which looks to slash the production of a key toxic protein widely viewed as a prime suspect in the development of the memory-wasting ailment.

Novartis nabs EU approval for melanoma-fighting cocktail bought from GSK

Novartis' melanoma duo Tafinlar and Mekinist scored a priority stateside review in July along with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Now the EU has given its final signoff on the combo for patients with a deadly form of the disease.

Novartis places $1B bet to push CLL med Arzerra into MS fray

Novartis' newly acquired Arzerra (ofatumumab) is up against some hefty competition in chronic lymphocytic leukemia (CLL). But the Swiss drugmaker has a plan for helping it achieve its sales potential.

Novartis shells out up to $1B to test GSK's Arzerra in MS

Thanks to the companies' recent multi-billion-dollar asset swap, Novartis already has the rights to former GlaxoSmithKline drug ofatumumab's cancer applications. But now, it's forking over up to $1 billion to gain full control of the med--currently marketed as Arzerra--and to test it as a therapy for multiple sclerosis.

GlaxoSmithKline flips an MS project to Novartis for up to $1B

Novartis is paying GlaxoSmithKline as much as $1 billion for the rights to a mid-stage multiple sclerosis treatment, betting it can develop an heir to the blockbuster Gilenya, soon to lose patent protection.

Novartis bets on a slumping Aveo in a $326M cancer deal

Over the past few years, Aveo Oncology has watched each of its most promising cancer treatments flame out, but pharma giant Novartis sees potential in one of the company's early-stage assets, and the Swiss drugmaker has come through with a deal worth up to $326 million to partner on the project.

Novartis and Cyndi Lauper just want psoriasis patients to have fun

Novartis is working hard to build up market share for new psoriasis med Cosentyx ahead of its forthcoming competition, and it's signed on '80s icon Cyndi Lauper to help.

Novartis goes '80s with Cyndi Lauper-led psoriasis campaign

How can girls with psoriasis have fun? '80s icon Cyndi Lauper says she knows--and she has teamed up with Novartis to talk about it.